Cysteine protease cathepsins in atherosclerosis-based vascular disease and its complications.

Atherosclerosis-based vascular disease is an inflammatory disease characterized by extensive remodeling of the extracellular matrix architecture of the arterial wall. Although matrix metalloproteinases and serine proteases participate in these pathological events, the discovery of cysteine protease cathepsins, such as cathepsins K, S, L, and B, and cystatin C, and their tissue distribution has suggested that at least some of them participate in cardiovascular disease. Studies on vascular cells have shown that atherosclerosis-associated inflammatory cytokines augment cysteinyl cathepsin expression and activity. Novel insight into cathepsin functions has been made possible by the generation and in-depth analysis of knockout and transgenic mice. These studies have provided direct evidence implicating cathepsins in atherosclerosis-based vascular disease through the activation, liberation, and modification of angiogenic growth factors, cytokines, and proteases associated with lipid metabolism, cell events (migration, invasion, proliferation, and apoptosis), angiogenesis, and matrix protein remodeling. Furthermore, evaluation of the feasibility of cathepsins as a diagnostic tool has revealed that the serum cathepsins S and L and the endogenous inhibitor cystatin C hold promise as biomarkers of coronary artery disease and aneurysm formation. The goal of this review is to summarize the available information regarding the mechanistic contributions of cathepsins in atherosclerosis-based vascular disease.

[1]  P. Libby,et al.  Cathepsin K Deficiency Reduces Elastase Perfusion–Induced Abdominal Aortic Aneurysms in Mice , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[2]  P. Libby,et al.  Cathepsin L Activity Is Essential to Elastase Perfusion–Induced Abdominal Aortic Aneurysms in Mice , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[3]  G. Shi,et al.  Cysteinyl cathepsins and mast cell proteases in the pathogenesis and therapeutics of cardiovascular diseases. , 2011, Pharmacology & therapeutics.

[4]  K. Okumura,et al.  Angiotensin Type 1 Receptor Blocker Reduces Intimal Neovascularization and Plaque Growth in Apolipoprotein E–Deficient Mice , 2011, Hypertension.

[5]  K. Okumura,et al.  Inhibition of mineralocorticoid receptor is a renoprotective effect of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor pitavastatin , 2011, Journal of hypertension.

[6]  D. Katritsis,et al.  Serum cathepsin levels in coronary artery ectasia. , 2010, International journal of cardiology.

[7]  B. Wang,et al.  Cystatin C Deficiency Promotes Epidermal Dysplasia in K14-HPV16 Transgenic Mice , 2010, PloS one.

[8]  T. Reinheckel,et al.  Specialized roles for cysteine cathepsins in health and disease. , 2010, The Journal of clinical investigation.

[9]  Jie Du,et al.  Simvastatin inhibited cardiac hypertrophy and fibrosis in apolipoprotein E-deficient mice fed a “Western-style diet” by increasing PPAR α and γ expression and reducing TC, MMP-9, and Cat S levels , 2010, Acta Pharmacologica Sinica.

[10]  ToyoakiMurohara,et al.  Exercise Training Stimulates Ischemia-Induced Neovascularization via Phosphatidylinositol 3-Kinase/Akt-Dependent Hypoxia-Induced Factor-1α Reactivation in Mice of Advanced Age , 2010 .

[11]  K. Okumura,et al.  Exercise Training Stimulates Ischemia-Induced Neovascularization via Phosphatidylinositol 3-Kinase/Akt-Dependent Hypoxia-Induced Factor-1&agr; Reactivation in Mice of Advanced Age , 2010, Circulation.

[12]  M. Percival,et al.  Pharmacological Inhibition of Cathepsin S Decreases Atherosclerotic Lesions in Apoe-/- Mice , 2010, Journal of cardiovascular pharmacology.

[13]  P. Libby,et al.  Cystatin C deficiency promotes inflammation in angiotensin II-induced abdominal aortic aneurisms in atherosclerotic mice. , 2010, The American journal of pathology.

[14]  K. Okumura,et al.  AT1 blockade attenuates atherosclerotic plaque destabilization accompanied by the suppression of cathepsin S activity in apoE-deficient mice. , 2010, Atherosclerosis.

[15]  L. Beckers,et al.  Cathepsin K gene disruption does not affect murine aneurysm formation. , 2010, Atherosclerosis.

[16]  J. Andersen,et al.  The Immunomodulatory Action of Sialostatin L on Dendritic Cells Reveals Its Potential to Interfere with Autoimmunity1 , 2009, The Journal of Immunology.

[17]  P. Libby,et al.  Deficiency of antigen-presenting cell invariant chain reduces atherosclerosis in mice. , 2009, Circulation.

[18]  P. Libby,et al.  Arterial and Aortic Valve Calcification Abolished by Elastolytic Cathepsin S Deficiency in Chronic Renal Disease , 2009, Circulation.

[19]  A. Yoganathan,et al.  Elevated cyclic stretch alters matrix remodeling in aortic valve cusps: implications for degenerative aortic valve disease. , 2009, American journal of physiology. Heart and circulatory physiology.

[20]  Michael C. Ostrowski,et al.  Free Cholesterol Accumulation in Macrophage Membranes Activates Toll-Like Receptors and p38 Mitogen-Activated Protein Kinase and Induces Cathepsin K , 2009, Circulation research.

[21]  G. Shi,et al.  Usefulness of serum cathepsin L as an independent biomarker in patients with coronary heart disease. , 2009, The American journal of cardiology.

[22]  J. Jukema,et al.  Leukocyte Cathepsin S Is a Potent Regulator of Both Cell and Matrix Turnover in Advanced Atherosclerosis , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[23]  C. Peters,et al.  Cathepsin K Activity-dependent Regulation of Osteoclast Actin Ring Formation and Bone Resorption* , 2009, Journal of Biological Chemistry.

[24]  C. Peters,et al.  Major Role of Cathepsin L for Producing the Peptide Hormones ACTH, β-Endorphin, and α-MSH, Illustrated by Protease Gene Knockout and Expression* , 2008, Journal of Biological Chemistry.

[25]  R. Maser,et al.  Acceleration of polycystic kidney disease progression in cpk mice carrying a deletion in the homeodomain protein Cux1. , 2008, American journal of physiology. Renal physiology.

[26]  K. Nozaki,et al.  Cathepsin B, K, and S Are Expressed in Cerebral Aneurysms and Promote the Progression of Cerebral Aneurysms , 2008, Stroke.

[27]  G. Salvesen,et al.  Cysteine Cathepsins Trigger Caspase-dependent Cell Death through Cleavage of Bid and Antiapoptotic Bcl-2 Homologues* , 2008, Journal of Biological Chemistry.

[28]  J. Kos,et al.  Cysteine protease cathepsin X modulates immune response via activation of β2 integrins , 2008, Immunology.

[29]  P. Moreau,et al.  Sequential Activation of Matrix Metalloproteinase 9 and Transforming Growth Factor &bgr; in Arterial Elastocalcinosis , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[30]  C. McNamara,et al.  Role of smooth muscle cells in the initiation and early progression of atherosclerosis. , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[31]  M. Waltham,et al.  Effect of statins on proteolytic activity in the wall of abdominal aortic aneurysms , 2008, The British journal of surgery.

[32]  Timur Shtatland,et al.  Osteogenesis Associates With Inflammation in Early-Stage Atherosclerosis Evaluated by Molecular Imaging In Vivo , 2007, Circulation.

[33]  M. Daemen,et al.  Cathepsin cysteine proteases in cardiovascular disease , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[34]  M. Linton,et al.  Angiotensin inhibition decreases progression of advanced atherosclerosis and stabilizes established atherosclerotic plaques. , 2007, Journal of the American Society of Nephrology : JASN.

[35]  Christoph Peters,et al.  Cathepsin L Deficiency Reduces Diet-Induced Atherosclerosis in Low-Density Lipoprotein Receptor-Knockout Mice , 2007, Circulation.

[36]  K. Okumura,et al.  Mechanisms Underlying the Impairment of Ischemia-Induced Neovascularization in Matrix Metalloproteinase 2–Deficient Mice , 2007, Circulation research.

[37]  W. Stark,et al.  Interaction between Human Cathepsins K, L, and S and Elastins , 2007, Journal of Biological Chemistry.

[38]  O. Vasiljeva,et al.  Emerging roles of cysteine cathepsins in disease and their potential as drug targets. , 2007, Current pharmaceutical design.

[39]  H. Izawa,et al.  Elastolytic Cathepsin Induction/Activation System Exists in Myocardium and Is Upregulated in Hypertensive Heart Failure , 2006, Hypertension.

[40]  Karine Clément,et al.  Cathepsin s promotes human preadipocyte differentiation: possible involvement of fibronectin degradation. , 2006, Endocrinology.

[41]  Bonnie F. Sloane,et al.  Cysteine cathepsins: multifunctional enzymes in cancer , 2006, Nature Reviews Cancer.

[42]  L. Matrisian,et al.  Matrix Metalloproteinase Inhibition Attenuates Aortic Calcification , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[43]  Chengcheng Hu,et al.  Increased serum cathepsin S in patients with atherosclerosis and diabetes. , 2006, Atherosclerosis.

[44]  X. Cheng,et al.  A Simple Method of Plaque Rupture Induction in Apolipoprotein E–Deficient Mice , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[45]  Shigeyoshi Itohara,et al.  Effect of MMP-2 Deficiency on Atherosclerotic Lesion Formation in ApoE-Deficient Mice , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[46]  Peter Libby,et al.  Inflammation and cellular immune responses in abdominal aortic aneurysms. , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[47]  R. Kalluri,et al.  Cathepsin S Controls Angiogenesis and Tumor Growth via Matrix-derived Angiogenic Factors* , 2006, Journal of Biological Chemistry.

[48]  D. Hanahan,et al.  Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. , 2006, Genes & development.

[49]  P. Libby,et al.  Cathepsin L expression and regulation in human abdominal aortic aneurysm, atherosclerosis, and vascular cells. , 2006, Atherosclerosis.

[50]  T. Murohara,et al.  Localization of Cysteine Protease, Cathepsin S, to the Surface of Vascular Smooth Muscle Cells by Association with Integrin ανβ3 , 2006 .

[51]  M. Daemen,et al.  Disruption of the Cathepsin K Gene Reduces Atherosclerosis Progression and Induces Plaque Fibrosis but Accelerates Macrophage Foam Cell Formation , 2005, Circulation.

[52]  M. Ko,et al.  Identification of target genes and a unique cis element regulated by IRF-8 in developing macrophages. , 2005, Blood.

[53]  K. Ley,et al.  Macrophage differentiation to foam cells. , 2005, Current pharmaceutical design.

[54]  R. Pérez-Montfort,et al.  Immunosuppressive activity of proteases in cervical carcinoma. , 2005, Gynecologic oncology.

[55]  Bonnie F. Sloane,et al.  Caveolin-1 mediates the expression and localization of cathepsin B, pro-urokinase plasminogen activator and their cell-surface receptors in human colorectal carcinoma cells , 2005, Journal of Cell Science.

[56]  E. Chavakis,et al.  Cathepsin L is required for endothelial progenitor cell–induced neovascularization , 2005, Nature Medicine.

[57]  Wei Li,et al.  Increased Expression and Translocation of Lysosomal Cathepsins Contribute to Macrophage Apoptosis in Atherogenesis , 2004, Annals of the New York Academy of Sciences.

[58]  Y. Nogi,et al.  Essential Role of p38 Mitogen-activated Protein Kinase in Cathepsin K Gene Expression during Osteoclastogenesis through Association of NFATc1 and PU.1* , 2004, Journal of Biological Chemistry.

[59]  Juan J. Badimon,et al.  Plaque Neovascularization Is Increased in Ruptured Atherosclerotic Lesions of Human Aorta: Implications for Plaque Vulnerability , 2004, Circulation.

[60]  M. Mäyränpää,et al.  Cysteine Protease Cathepsin F Is Expressed in Human Atherosclerotic Lesions, Is Secreted by Cultured Macrophages, and Modifies Low Density Lipoprotein Particles in Vitro* , 2004, Journal of Biological Chemistry.

[61]  P. Libby,et al.  Lysosomal Cysteine Proteases in Atherosclerosis , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[62]  Y. Tintut,et al.  Vascular calcification: mechanisms and clinical ramifications. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[63]  A. M. Romanic,et al.  Cathepsin S expression is up-regulated following balloon angioplasty in the hypercholesterolemic rabbit. , 2004, Cardiovascular research.

[64]  D. Hanahan,et al.  Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. , 2004, Cancer cell.

[65]  P. Kovanen,et al.  Cathepsins F and S block HDL3-induced cholesterol efflux from macrophage foam cells. , 2003, Biochemical and biophysical research communications.

[66]  Bonnie F. Sloane,et al.  Mutant K-ras regulates cathepsin B localization on the surface of human colorectal carcinoma cells. , 2003, Neoplasia.

[67]  S. Itohara,et al.  Deficiency of Gelatinase A Suppresses Smooth Muscle Cell Invasion and Development of Experimental Intimal Hyperplasia , 2003, Circulation.

[68]  J. Deussing,et al.  Thyroid functions of mouse cathepsins B, K, and L. , 2003, The Journal of clinical investigation.

[69]  P. Libby,et al.  Deficiency of the Cysteine Protease Cathepsin S Impairs Microvessel Growth , 2003, Circulation research.

[70]  Makoto Naito,et al.  Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. , 2003, The Journal of clinical investigation.

[71]  A. Rudensky,et al.  Differential Regulation of Cathepsin S and Cathepsin L in Interferon γ–treated Macrophages , 2003, Journal of Experimental Medicine.

[72]  G. Salvesen,et al.  Regulating cysteine protease activity: essential role of protease inhibitors as guardians and regulators. , 2002, Current pharmaceutical design.

[73]  A. Steptoe,et al.  Circulating Human Heat Shock Protein 60 in the Plasma of British Civil Servants: Relationship to Physiological and Psychosocial Stress , 2002, Circulation.

[74]  S. S. Chauhan,et al.  Identification and characterization of a novel human cathepsin L splice variant. , 2002, Gene.

[75]  R. Gordon,et al.  Cathepsin k is a critical protease in synovial fibroblast-mediated collagen degradation. , 2001, The American journal of pathology.

[76]  R. Locksley,et al.  Regulation of CD1 function and NK1.1(+) T cell selection and maturation by cathepsin S. , 2001, Immunity.

[77]  J. Lindholt,et al.  Cystatin C deficiency is associated with the progression of small abdominal aortic aneurysms , 2001, The British journal of surgery.

[78]  D. Turk,et al.  Lysosomal cysteine proteases: facts and opportunities , 2001, The EMBO journal.

[79]  E. Caler,et al.  Plasma Membrane Repair Is Mediated by Ca2+-Regulated Exocytosis of Lysosomes , 2001, Cell.

[80]  F. Spinale,et al.  Matrix Metalloproteinase Inhibition Attenuates Left Ventricular Remodeling and Dysfunction in a Rat Model of Progressive Heart Failure , 2001, Circulation.

[81]  J. Tonn,et al.  Production of MMPs in Human Cerebral Endothelial Cells and Their Role in Shedding Adhesion Molecules , 2001, Journal of neuropathology and experimental neurology.

[82]  Roger D. Kamm,et al.  The Impact of Calcification on the Biomechanical Stability of Atherosclerotic Plaques , 2001, Circulation.

[83]  P. Libby.  Changing concepts of atherogenesis , 2000, Journal of internal medicine.

[84]  P. Libby,et al.  Cystatin C deficiency in human atherosclerosis and aortic aneurysms. , 1999, The Journal of clinical investigation.

[85]  G. Dranoff,et al.  Cathepsin S required for normal MHC class II peptide loading and germinal center development. , 1999, Immunity.

[86]  A. Rudensky,et al.  Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. , 1999, Immunity.

[87]  P. Libby,et al.  Death of smooth muscle cells and expression of mediators of apoptosis by T lymphocytes in human abdominal aortic aneurysms. , 1999, Circulation.

[88]  P. Libby,et al.  Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. , 1998, The Journal of clinical investigation.

[89]  I. Mellman,et al.  Developmental Regulation of Invariant Chain Proteolysis Controls MHC Class II Trafficking in Mouse Dendritic Cells , 1998, Cell.

[90]  P. Carmeliet,et al.  Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation , 1997, Nature Genetics.

[91]  M. Aoki,et al.  Systemic administration of ribbon-type decoy oligodeoxynucleotide against nuclear factor κB and ets prevents abdominal aortic aneurysm in rat model. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[92]  H. Izawa,et al.  Cardiovascular , Pulmonary and Renal Pathology Superoxide-Dependent Cathepsin Activation Is Associated with Hypertensive Myocardial Remodeling and Represents a Target for Angiotensin II Type 1 Receptor Blocker Treatment , 2010 .

[93]  中村 香江.  Statin prevents plaque disruption in apoE-knockout mouse model through pleiotropic effect on acute inflammation , 2009 .

[94]  T. Murohara,et al.  Localization of cysteine protease, cathepsin S, to the surface of vascular smooth muscle cells by association with integrin alphanubeta3. , 2006, The American journal of pathology.

[95]  X. Cheng,et al.  Increased expression of elastolytic cysteine proteases, cathepsins S and K, in the neointima of balloon-injured rat carotid arteries. , 2004, The American journal of pathology.

[96]  Bonnie F. Sloane,et al.  Cell-surface cathepsin B: understanding its functional significance. , 2003, Current topics in developmental biology.

[97]  J. Kos,et al.  Lysosomal cathepsins: structure, role in antigen processing and presentation, and cancer. , 2002, Advances in enzyme regulation.

[98]  L. Chyczewskî,et al.  Distribution, activity and concentration of cathepsin B and cystatin C in the wall of aortic aneurysm. , 1999, Polish journal of pathology : official journal of the Polish Society of Pathologists.

[99]  M. Gacko,et al.  Cathepsin D and Cathepsin L Activities in Aortic Aneurysm Wall and Parietal Thrombus , 1998, Clinical chemistry and laboratory medicine.

[100]  Bonnie F. Sloane,et al.  Identification of two new exons and multiple transcription start points in the 5'-untranslated region of the human cathepsin-B-encoding gene. , 1995, Gene.